Passage Bio (PASG) Expected to Post Earnings on Monday

Posted by George Bondi on Aug 2nd, 2026

Passage Bio (NASDAQ:PASG – Get Free Report) is anticipated to announce its Q2 2026 results before the market opens on Monday, August 3rd. Analysts expect Passage Bio to announce earnings of ($2.27) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 7, 2026 at 9:30 AM ET.

Passage Bio (NASDAQ:PASG – Get Free Report) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($2.36) EPS for the quarter, beating the consensus estimate of ($2.76) by $0.40. On average, analysts expect Passage Bio to post $-9 EPS for the current fiscal year and $-9 EPS for the next fiscal year.

Passage Bio Price Performance

PASG stock opened at $4.47 on Friday. The business has a 50-day moving average price of $5.14 and a 200 day moving average price of $7.39. The company has a market capitalization of $14.35 million, a P/E ratio of -0.38 and a beta of 1.42. Passage Bio has a 1-year low of $3.29 and a 1-year high of $20.00.

Insider Buying and Selling at Passage Bio

In related news, major shareholder Lynx1 Capital Management Lp acquired 50,055 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The shares were bought at an average price of $4.12 per share, with a total value of $206,226.60. Following the completion of the transaction, the insider directly owned 673,759 shares in the company, valued at $2,775,887.08. This trade represents a 8.03% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Passage Bio

Large investors have recently added to or reduced their stakes in the company. Quadrature Capital Ltd purchased a new stake in shares of Passage Bio during the fourth quarter valued at about $148,000. Squarepoint Ops LLC bought a new stake in shares of Passage Bio in the 3rd quarter valued at about $188,000. Geode Capital Management LLC grew its position in shares of Passage Bio by 15.1% in the 4th quarter. Geode Capital Management LLC now owns 31,397 shares of the company’s stock worth $371,000 after buying an additional 4,114 shares during the last quarter. Yiheng Capital Management L.P. purchased a new position in shares of Passage Bio in the 4th quarter worth approximately $405,000. Finally, Renaissance Technologies LLC raised its stake in shares of Passage Bio by 8.2% during the 4th quarter. Renaissance Technologies LLC now owns 109,089 shares of the company’s stock worth $1,287,000 after acquiring an additional 8,300 shares in the last quarter. 53.48% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on PASG. Weiss Ratings reiterated a “sell (d-)” rating on shares of Passage Bio in a report on Wednesday, June 24th. Guggenheim lowered shares of Passage Bio from a “buy” rating to a “neutral” rating in a report on Wednesday, June 10th. UBS Group cut shares of Passage Bio to a “neutral” rating in a research report on Wednesday, June 10th. Oppenheimer dropped their price objective on shares of Passage Bio from $30.00 to $15.00 and set an “outperform” rating on the stock in a research note on Tuesday, April 21st. Finally, TD Cowen lowered shares of Passage Bio from a “buy” rating to a “hold” rating in a report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Passage Bio presently has an average rating of “Hold” and a consensus price target of $13.25.

View Our Latest Stock Analysis on PASG

About Passage Bio

(Get Free Report)

Passage Bio is a clinical-stage biotechnology company focused on the development of gene therapies to treat rare, monogenic central nervous system and neuromuscular disorders. The company applies its in-house gene therapy platform to design and engineer adeno-associated virus (AAV)–based vectors that restore or replace defective genes, aiming to deliver durable treatments with a single administration.

The company’s lead programs include PBGM01, an AAV9-based therapy for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), which is conducting a first-in-human study to assess safety and potential therapeutic benefit.